Garsorasib for KRAS G12C lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (stage IIIB or IV) non-small cell lung cancer.
- Your cancer has a specific gene change called KRAS G12C.
- You have not yet had any treatment for your advanced lung cancer.
- You are in good enough health to carry out daily activities (ECOG 0-1).
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted medicines for advanced non-small cell lung cancer with a specific gene change (KRAS G12C). The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new targeted pill (GFH375) alone or with another drug for people with a specific gene change (KRAS G12D) in advanced lung cancer. It aims to shrink or slow the cancer, possibly better than current standard treatments.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests an experimental drug for advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It is for people whose cancer has not responded to standard treatments.
Hear when a new Local Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.